Pegfilgrastim biosimilar - Jiangsu Hengrui Medicine Co.

Drug Profile

Pegfilgrastim biosimilar - Jiangsu Hengrui Medicine Co.

Alternative Names: HHPG-19K; Pegylated rhG-CSF - Jiangsu Hengrui

Latest Information Update: 11 Sep 2015

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Neutropenia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 May 2015 Phase-III development is ongoing in China
  • 01 Jan 2013 Jiangsu Hengrui Medicine Co. completes a phase III trial in Neutropenia (chemotherapy-induced, prevention) in China (NCT01611051)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top